News

GlobalData on MSN1mon
Dyne’s DMD trial advances patient mobility and dystrophin expression
Dyne is hoping that a further readout later in 2025 will set the company up to submit for accelerated approval in early 2026 ...
Yahoo Finance12d
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with ...